论文部分内容阅读
目的: 研究20(R)-人参皂甙Rg3人体药代动力学。方法: 高效液相色谱-紫外检测法。结果: 8名健康志愿者单剂量口服3.2 mg穔g-1 20(R)-人参皂甙Rg3,其药时曲线符合口服吸收有滞后时间的二房室模型,Tmax为0.660.10 h,Cmax为166 ng穖L-1,T1/2a 为0.460.12 h,T1/2b 为4.91.1 h,T1/2(Ka) 为0.280.04 h,AUC0-为7726 ng穖L-1穐;6名健康志愿者单剂量口服0.8 mg穔g-1 Rg3,由于血药浓度低,可测数据点少,未进行模型模拟;两组给药剂量与相应Cmax实测值比较,二者成正比关系。结论: 本品口服吸收快,消除也较快,但血药浓度很低。在所试剂量范围内,20(R)-人参皂甙Rg3属一级动力学吸收﹑消除过程。
Objective: To study the pharmacokinetics of 20 (R) -ginsenoside Rg3 in human. Methods: High performance liquid chromatography - UV detection. Results: Eight healthy volunteers were given a single oral dose of 3.2 mg 穔 g-1 20 (R) -ginsenoside Rg3 with a pharmacokinetic profile in line with the two-compartment model of oral absorption with lag time, with a Tmax of 0.660.10 h and a Cmax of 166 ng 穖 L-1, T1 / 2a was 0.460.12 h, T1 / 2b was 4.91.1 h, T1 / 2 (Ka) was 0.280.04 h and AUC0- was 7726 ng 穖 L-1 穐; The single dose of oral administration of 0.8 mg 穔 g-1 Rg3, due to low blood concentration, measurable data points less, no model simulation; dose of the two groups compared with the corresponding Cmax measured values, the two is proportional relationship. Conclusion: This product oral absorption faster, faster elimination, but low blood concentration. Within the dosage range, 20 (R) - ginsenoside Rg3 is a first order kinetic absorption and elimination process.